Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 853-864

  Kanno, Hiromi ^a   Nishihara, Hiroshi ^b   Wang, Lei ^b   Yuzawa, Sayaka ^a   Kobayashi, Hiroyuki ^c   Tsuda, Masumi ^a   Kimura, Taichi ^a   Tanino, Mishie ^a   Terasaka, Shunsuke ^a,b   Tanaka, Shinya ^c  

^a Department of Pathology   (Japan)

^b Laboratory of Translational Pathology   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

apoptosis; CD163; G CSF; malignancy; meningioma

Indexed keywords

CD163 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MENINGIOMA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY;

APOPTOSIS; CD163; G-CSF; MALIGNANCY; MENINGIOMA;

ADULT; AGED; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM GRADING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84879370655     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not028     Document Type: Article

References (52)

1. Zwadlo G, Voegeli R, Schulze Osthoff K, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 1987; 55(6): 295-304. (Pubitemid 18087127)
2. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.AmJ Surg Pathol. 2005; 29(5): 617-624. (Pubitemid 40577871)
3. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010; 47(7-8): 1650-1660.
4. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001; 409(6817): 198-201. (Pubitemid 32144285)
5. Fabriek BO, van Bruggen R, Deng DM, et al. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood. 2009; 113(4): 887-892.
6. Fabriek BO, Polfliet MM, Vloet RP, et al. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood. 2007; 109(12): 5223-5229. (Pubitemid 46890540)
7. Bover LC, Cardo-Vila M, Kuniyasu A, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007; 178(12): 8183-8194. (Pubitemid 46898091)
8. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009; 207(1): 103-110.
9. Fujii N, Shomori K, Shiomi T, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med. 2012; 2(10): 1600-0714.
10. Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009; 27(20): 3330-3337.
11. Buddingh EP, Kuijjer ML, Duim RA, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011; 17(8): 2110-2119.
12. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer. 2009; 125(8): 1826-1831.
13. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008; 123(4): 780-786. (Pubitemid 352032402)
14. Maniecki MB, Etzerodt A, Ulhoi BP, et al. Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012; 131(10): 2320-2323.
15. Aghi MK, Carter BS, Cosgrove GR, et al. Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009; 64(1): 56-60, discussion 60.
16. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009; 9(3): 231-240.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. 4th Edition: IARC Press, Lyons; 2007.
18. Pasquier D, Bijmolt S, Veninga T, et al. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008; 71(5): 1388-1393.
19. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol. 2004; 63(4): 275-286. (Pubitemid 38429025)
20. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg. 2004; 101(2): 210-218. (Pubitemid 38970995)
21. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010; 96(2): 211-217.
22. Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012; 106(2): 409-415.
23. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009; 11(6): 853-860.
24. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012; 109(1): 187-193.
25. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012; 109(1): 63-70.
26. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg. Pathol. 1997; 21(12): 1455-1465. (Pubitemid 27528256)
27. Van den Heuvel MM, Tensen CP, van As JH, et al. Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol. 1999; 66(5): 858-866. (Pubitemid 29532050)
28. Boneberg EM, Hartung T. Molecular aspects of anti-inflammatory action of G-CSF. Inflamm Res. 2002; 51(3): 119-128. (Pubitemid 34297850)
29. Obermueller E, Vosseler S, Fusenig NE, Mueller MM. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 2004; 64(21): 7801-7812. (Pubitemid 39446913)
30. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006; 66(16): 8026-8036. (Pubitemid 44299167)
31. Chakraborty A, Guha S. Granulocyte colony-stimulating factor/ granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology. 2007; 69(6): 1210-1215. (Pubitemid 46891579)
32. Wang J, Yao L, Zhao S, et al. Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. Cancer Biol Ther. 2012; 13(6): 389-400.
33. Robinson WA. Granulocytosis in neoplasia. Ann N Y Acad Sci. 1974; 230: 212-218.
34. Takagi Y, Nakamura H, Miwa K, et al. A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy. Thorac Cardiovasc Surg. 2010; 58(5): 304-306.
35. Matsuda A, Sasajima K, Matsutani T, et al. Aggressive undifferentiated colon carcinoma producing granulocyte-colony stimulating factor: report of a case. Surg Today. 2009; 39(11): 990-993.
36. Kohno M, Shirabe K, Mano Y, et al. Granulocyte colony-stimulatingfactor- producing hepatocellular carcinoma with extensive sarcomatous changes: report of a case. [published online ahead of print May 26, 2012]. Surg Today. 2012. doi: 10.1007/s00595-012-0202-0.
37. Kawaguchi M, Asada Y, Terada T, et al. Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. Int J Clin Oncol. 2010; 15(2): 191-195.
38. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun. 1999; 256(1): 110-113. (Pubitemid 29298926)
39. Hintz KA, Rassias AJ, Wardwell K, et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 2002; 72(4): 711-717. (Pubitemid 36277842)
40. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, De Keyser F. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum. 2004; 50(5): 1611-1623. (Pubitemid 38608084)
41. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Expression of CD163 in the liver of patients with viral hepatitis. Pathol Res Pract. 2005; 201(5): 379-384. (Pubitemid 40862463)
42. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood. 2002; 99(1): 378-380. (Pubitemid 34533008)
43. Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008; 8(5): 377-386. (Pubitemid 351589699)
44. Rachkovsky M, Sodi S, Chakraborty A, et al. Melanoma x macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis. 1998; 16(4): 299-312. (Pubitemid 28255525)
45. Ding J, Jin W, Chen C, Shao Z, Wu J. Tumor associated macrophage x cancer cell hybrids may acquire cancer stem cell properties in breast cancer. PLoS One. 2012; 7(7): e41942.
46. Pham MH, Zada G, Mosich GM, et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus. 2011; 30(5): E7.
47. Smith JS, Lal A, Harmon-Smith M, Bollen AW, McDermott MW. Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg. 2007; 106(6): 1034-1040. (Pubitemid 46871117)
48. Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci. 2001; 8(Suppl 1): 49-53.
49. Lusis EA, Chicoine MR, Perry A. High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol. 2005; 73(3): 219-223. (Pubitemid 40974017)
50. Wernicke AG, Dicker AP, Whiton M, et al. Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol. 2010; 5: 46.
51. Braun B, Lange M, Oeckler R, Mueller MM. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J Neurooncol. 2004; 68(2): 131-140. (Pubitemid 39137337)
52. Schiffer D, Ghimenti C, Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol. 2005; 73(2): 125-130. (Pubitemid 40974032) Technology (FIRST Program)